These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26377400)

  • 1. The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
    Perdoncin E; Seth M; Dixon S; Cannon L; Khandelwal A; Riba A; David S; Wohns D; Gurm H
    Eur Heart J; 2016 Jun; 37(24):1902-9. PubMed ID: 26377400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of worsening renal dysfunction on the comparative efficacy of bivalirudin and platelet glycoprotein IIb/IIIa inhibitors: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
    Perdoncin E; Zhang M; Riba A; LaLonde TA; Grines CL; Gurm HS
    Circ Cardiovasc Interv; 2013 Dec; 6(6):688-93. PubMed ID: 24280966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.
    Sukul D; Seth M; Schreiber T; Khandelwal A; Cannon LA; LaLonde TA; Gurm HS
    Catheter Cardiovasc Interv; 2017 Nov; 90(5):724-732. PubMed ID: 28303632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
    Gurm HS; Smith DE; Chetcuti SJ; Share D; Khanal S; Riba A; Carter AJ; Lalonde T; Kline-Rogers E; O'Donnell M; O'Neill W; Safian R; Moscucci M;
    J Interv Cardiol; 2007 Jun; 20(3):197-203. PubMed ID: 17524111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between arterial access site and anticoagulation strategy on major bleeding and mortality: A historical cohort analysis in the Veteran population.
    Bagai J; Little B; Banerjee S
    Cardiovasc Revasc Med; 2018; 19(1 Pt B):95-101. PubMed ID: 28624360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
    Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
    Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
    J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
    Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
    BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Of Bleeding Avoidance Strategies with age-related bleeding and In-hospital mortality in patients undergoing percutaneous coronary Interventions.
    Khambatta S; Othman H; Seth M; Lalonde T; Rosman HS; Gurm HS; Mehta RH;
    Cardiovasc Revasc Med; 2016 Jun; 17(4):233-40. PubMed ID: 26994504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
    Xu H; Wang B; Yang J; Ma S; Xie X
    PLoS One; 2017; 12(1):e0169951. PubMed ID: 28095453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of anticoagulants and outcomes in STEMI patients undergoing PPCI in the US hospitals: Bivalirudin, heparin plus GPI or heparin alone?
    Plent S; Mitchell M; Fan W; Werner R
    Hosp Pract (1995); 2015; 43(3):164-71. PubMed ID: 26190670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radial PCI and the obesity paradox: Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    McDonagh JR; Seth M; LaLonde TA; Khandewal AK; Wohns DH; Dixon SR; Gurm HS
    Catheter Cardiovasc Interv; 2016 Feb; 87(2):211-9. PubMed ID: 26010906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost analysis of bivalirudin versus reference anticoagulants without GP IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention for acute coronary syndrome in routine clinical practice. Pompidou registry.
    Puymirat E; Cohen S; Védrenne G; Caruba T; Sabatier B; Danchin N; Durand E
    Ann Cardiol Angeiol (Paris); 2013 Apr; 62(2):89-94. PubMed ID: 23245394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
    J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin during primary PCI in acute myocardial infarction.
    Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
    N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.